| Gina Marie Morgan, DPM | |
|
8096 Zuber Rd, Benton, AR 72019-1683 | |
| (845) 461-9574 | |
| Not Available |
| Full Name | Gina Marie Morgan |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 15 Years |
| Location | 8096 Zuber Rd, Benton, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093949448 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 277 (Arkansas) | Primary |
| Provider Name | Bradley Bibb Md Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1699097436 PECOS PAC ID: 4789715285 Enrollment ID: O20100628000488 |
News Archive
The human eye lens consists of a highly concentrated mix of several proteins. Protective proteins prevent these proteins from aggregating and clumping. If this protective function fails, the lens blurs and the patient develops cataracts. Two research groups at the Department of Chemistry of the Technische Universitaet Muenchen (TUM) have succeeded in explaining the molecular architecture of this kind of protective protein.
For the second year, Aetna is sponsoring children's activities at the US Open and is determined to deliver twice the fun as part of its three-year sponsorship agreement with the United States Tennis Association (USTA).
Many cancers, including colon, prostate, and leukemia, continue to grow unchecked because they do not respond to a signal to die and stop proliferating from Transforming Growth Factor-beta (TGF-b).
BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.
› Verified 7 days ago
| Provider Name | Access Medical Clinic Arkansas Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1578007647 PECOS PAC ID: 5890077093 Enrollment ID: O20170124001288 |
News Archive
The human eye lens consists of a highly concentrated mix of several proteins. Protective proteins prevent these proteins from aggregating and clumping. If this protective function fails, the lens blurs and the patient develops cataracts. Two research groups at the Department of Chemistry of the Technische Universitaet Muenchen (TUM) have succeeded in explaining the molecular architecture of this kind of protective protein.
For the second year, Aetna is sponsoring children's activities at the US Open and is determined to deliver twice the fun as part of its three-year sponsorship agreement with the United States Tennis Association (USTA).
Many cancers, including colon, prostate, and leukemia, continue to grow unchecked because they do not respond to a signal to die and stop proliferating from Transforming Growth Factor-beta (TGF-b).
BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.
› Verified 7 days ago
| Provider Name | Access Medical Clinic Arkansas Ltc Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1114578929 PECOS PAC ID: 0547618175 Enrollment ID: O20231208000065 |
News Archive
The human eye lens consists of a highly concentrated mix of several proteins. Protective proteins prevent these proteins from aggregating and clumping. If this protective function fails, the lens blurs and the patient develops cataracts. Two research groups at the Department of Chemistry of the Technische Universitaet Muenchen (TUM) have succeeded in explaining the molecular architecture of this kind of protective protein.
For the second year, Aetna is sponsoring children's activities at the US Open and is determined to deliver twice the fun as part of its three-year sponsorship agreement with the United States Tennis Association (USTA).
Many cancers, including colon, prostate, and leukemia, continue to grow unchecked because they do not respond to a signal to die and stop proliferating from Transforming Growth Factor-beta (TGF-b).
BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gina Marie Morgan, DPM 8096 Zuber Rd, Benton, AR 72019-1683 Ph: (845) 461-9574 | Gina Marie Morgan, DPM 8096 Zuber Rd, Benton, AR 72019-1683 Ph: (845) 461-9574 |
News Archive
The human eye lens consists of a highly concentrated mix of several proteins. Protective proteins prevent these proteins from aggregating and clumping. If this protective function fails, the lens blurs and the patient develops cataracts. Two research groups at the Department of Chemistry of the Technische Universitaet Muenchen (TUM) have succeeded in explaining the molecular architecture of this kind of protective protein.
For the second year, Aetna is sponsoring children's activities at the US Open and is determined to deliver twice the fun as part of its three-year sponsorship agreement with the United States Tennis Association (USTA).
Many cancers, including colon, prostate, and leukemia, continue to grow unchecked because they do not respond to a signal to die and stop proliferating from Transforming Growth Factor-beta (TGF-b).
BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.
› Verified 7 days ago